Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Bristol-Myers Squibb Co    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Kyowa Hakko Kirin signs clinical trial collaboration agreement with Bristol-Myers Squibb

07/31/2015 | 05:51am US/Eastern

Kyowa Hakko Kirin, a Japan-based pharmaceutical and biotechnology company, has signed a clinical trial collaboration agreement with Bristol-Myers Squibb, a global biopharmaceutical company.

It was reported yesterday that the contract has been signed to conduct a Phase I/II combination trial with mogamulizumab, an anti-CCR4 antibody and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor to treat advanced or metastatic solid tumours. Mogamulizumab is a new, humanised mAb directed against CC chemokine receptor type 4 (CCR4).

The trial will concentrate on assessing the safety, tolerability and anti-tumour activity of combining mogamulizumab and Opdivo as a potential treatment option for these patients.

.

(c) 2015 M2 COMMUNICATIONS, source M2 PressWIRE

React to this article
Latest news on BRISTOL-MYERS SQUIBB CO
07/31 Kyowa Hakko Kirin signs clinical trial collaboration agreement with Bristol-M..
07/31 BRISTOL MYERS SQUIBB : Reported that European Medicines Agency Validates and Gra..
07/30 BRISTOL MYERS SQUIBB : European Commission Approves Nivolumab BMS, the First PD-..
07/30DJAstraZeneca Boosted by Licensing Deals -- 2nd Update
07/30DJAstraZeneca Boosted by Licensing Deals -- Update
07/30 BRISTOL MYERS SQUIBB : Reported that European Medicines Agency Validates and Gra..
07/30DJAstraZeneca Boosted by Licensing Deals
07/29 Kyowa Hakko Kirin, Bristol-Myers Announce Immuno-Oncology Clinical Collaborat..
07/29 BRISTOL MYERS SQUIBB : Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immun..
07/29 BRISTOL MYERS SQUIBB : New Pharmaceutical Research Study Findings Recently Were ..
Advertisement
Chart
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Income Statement Evolution
More Financials